selected publications
- Pre-treatment metastatic biopsy: a step towards precision oncology for urothelial cancer. Nature reviews. Urology. 2024 Review GET IT
- The interplay of mutagenesis and ecDNA shapes urothelial cancer evolution. Nature. 2024 Academic Article GET IT
- FGFR Inhibition in Urothelial Carcinoma. European urology. 2024 Review GET IT
- Urine Biopsy as Dynamic Biomarker to Enhance Clinical Staging of Bladder Cancer in Radical Cystectomy Candidates. JCO precision oncology. 2024 Academic Article GET IT
- The evolution of metastatic upper tract urothelial carcinoma through genomic-transcriptomic and single-cell protein markers analysis. Nature communications. 2024 Academic Article GET IT
- A combinatorial genetic strategy for exploring complex genotype-phenotype associations in cancer. Nature genetics. 2024 Academic Article GET IT
- A new era in the treatment of urothelial carcinoma. Urologic oncology. 2023 Review GET IT
- Novel Use of Circulating Tumor DNA to Identify Muscle-invasive and Non-organ-confined Upper Tract Urothelial Carcinoma. European urology. 2023 Academic Article GET IT
- Immunotherapy in the Treatment of Localized Genitourinary Cancers. JAMA oncology. 2023 Academic Article GET IT
- A Pilot Study on Hyperthermic Intraperitoneal Chemotherapy after Radical or Partial Cystectomy with Pelvic Lymph Node Dissection for High-risk Muscle-invasive Bladder Cancer. European urology. 2023 Letter GET IT
- Combinatorial genetic strategy accelerates the discovery of cancer genotype-phenotype associations. 2023 GET IT
- Immune Checkpoint Inhibitors and Long-term Survival of Patients With Metastatic Urothelial Cancer. JAMA network open. 2023 Academic Article GET IT
- Circulating and urinary tumour DNA in urothelial carcinoma - upper tract, lower tract and metastatic disease. Nature reviews. Urology. 2023 Review GET IT
- The cytidine deaminase APOBEC3G contributes to cancer mutagenesis and clonal evolution in bladder cancer. Cancer research. 2022 Academic Article GET IT
- Tumor Infiltrating Myeloid Cells Confer de novo Resistance to PD-L1 Blockade through EMT-stromal and Tgf-beta Dependent Mechanisms. Molecular cancer therapeutics. 2022 Academic Article GET IT
- Recurrent exon-deleting activating mutations in AHR act as drivers of urinary tract cancer. Scientific reports. 2022 Academic Article GET IT
- Loss of function mutations in CDKN1A are permissive for APOBEC3-induced mutagenesis in urothelial carcinoma. American journal of cancer research. 2022 Editorial Article GET IT
- The genomic landscape of metastatic clear cell renal cell carcinoma after systemic therapy. Molecular oncology. 2022 Academic Article GET IT
- Serial ctDNA analysis predicts clinical progression in patients with advanced urothelial carcinoma. British journal of cancer. 2022 Academic Article GET IT
- Functional comparison of exome capture-based methods for transcriptomic profiling of formalin-fixed paraffin-embedded tumors. NPJ genomic medicine. 2021 Academic Article GET IT
- Validation of a Circulating Tumor DNA-Based Next-Generation Sequencing Assay in a Cohort of Patients with Solid tumors: A Proposed Solution for Decentralized Plasma Testing. The oncologist. 2021 Academic Article GET IT
- Impact of Use of Antibiotics on Response to Immune Checkpoint Inhibitors and Tumor Microenvironment. American journal of clinical oncology. 2021 Academic Article GET IT
-
Spectrum of FGFR2/3 Alterations in Cell-Free DNA of Patients with Advanced Urothelial Carcinoma.
Bladder cancer (Amsterdam, Netherlands).
2021
Academic Article
GET IT
Times cited: 5 -
Common germline-somatic variant interactions in advanced urothelial cancer.
Nature communications.
2020
Academic Article
GET IT
Times cited: 22 -
Integration of whole-exome and anchored PCR-based next generation sequencing significantly increases detection of actionable alterations in precision oncology.
Translational oncology.
2020
Academic Article
GET IT
Times cited: 9 -
Epithelial plasticity can generate multi-lineage phenotypes in human and murine bladder cancers.
Nature communications.
2020
Academic Article
GET IT
Times cited: 42 -
Genomic heterogeneity in bladder cancer: challenges and possible solutions to improve outcomes.
Nature reviews. Urology.
2020
Information Resource
GET IT
Times cited: 116 -
A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns.
Nature communications.
2020
Academic Article
GET IT
Times cited: 128 -
Pan-cancer analysis of whole genomes.
Nature.
2020
Academic Article
GET IT
Times cited: 1726 -
The emerging landscape of germline variants in urothelial carcinoma: Implications for genetic testing.
Cancer treatment and research communications.
2020
Academic Article
GET IT
Times cited: 2 -
Integrative Molecular Analysis of Patients With Advanced and Metastatic Cancer.
JCO precision oncology.
2019
Academic Article
GET IT
Times cited: 32 -
Clinical features of neuroendocrine prostate cancer.
European journal of cancer.
2019
Academic Article
GET IT
Times cited: 204 -
Proteomic and genomic signatures of repeat instability in cancer and adjacent normal tissues.
Proceedings of the National Academy of Sciences of the United States of America.
2019
Academic Article
GET IT
Times cited: 12 -
Cancer-Specific Thresholds Adjust for Whole Exome Sequencing-based Tumor Mutational Burden Distribution.
JCO precision oncology.
2019
Academic Article
GET IT
Times cited: 26 -
Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling.
Nature communications.
2019
Academic Article
GET IT
Times cited: 141 -
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association with Clinical Outcomes: A Pilot Study.
European urology oncology.
2019
Academic Article
GET IT
Times cited: 13 -
Treatment resistance in urothelial carcinoma: an evolutionary perspective.
Nature reviews. Clinical oncology.
2018
Information Resource
GET IT
Times cited: 18 -
Characterization of metastatic urothelial carcinoma via comprehensive genomic profiling of circulating tumor DNA.
Cancer.
2018
Academic Article
GET IT
Times cited: 77 -
Metastasectomy in older adults with urothelial carcinoma: Population-based analysis of use and outcomes.
Urologic oncology.
2017
Academic Article
GET IT
Times cited: 17 -
Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models.
JCO precision oncology.
2017
Academic Article
GET IT
Times cited: 43 -
Personalized In Vitro and In Vivo Cancer Models to Guide Precision Medicine.
Cancer discovery.
2017
Academic Article
GET IT
Times cited: 722 - Immune-checkpoint blockade in cisplatin-ineligible patients with urothelial cancer. Lancet (London, England). 2016 Article GET IT
-
Clonal evolution of chemotherapy-resistant urothelial carcinoma.
Nature genetics.
2016
Academic Article
GET IT
Times cited: 229 -
Effect of tumor location on survival in urinary bladder adenocarcinoma: A population-based analysis.
Urologic oncology.
2016
Academic Article
GET IT
Times cited: 16 -
Blocking immune checkpoints in prostate, kidney, and urothelial cancer: An overview.
Urologic oncology.
2016
Information Resource
GET IT
Times cited: 43 -
Application of next-generation sequencing in gastrointestinal and liver tumors.
Cancer letters.
2016
Information Resource
GET IT
Times cited: 3 -
Sacituzumab Govitecan, a Novel Antibody--Drug Conjugate, in Patients With Metastatic Platinum-Resistant Urothelial Carcinoma.
Clinical genitourinary cancer.
2015
Academic Article
GET IT
Times cited: 45 -
Radical Cystectomy for Bladder Cancer in Patients With and Without a History of Pelvic Irradiation: Survival Outcomes and Diversion-related Complications.
Urology.
2015
Academic Article
GET IT
Times cited: 10 -
Whole-Exome Sequencing of Metastatic Cancer and Biomarkers of Treatment Response.
JAMA oncology.
2015
Academic Article
GET IT
Times cited: 229 -
Perioperative Bridging Anticoagulation in Patients with Atrial Fibrillation.
The New England journal of medicine.
2015
Academic Article
GET IT
Times cited: 895 -
Recurrence patterns after open and robot-assisted radical cystectomy for bladder cancer.
European urology.
2015
Academic Article
GET IT
Times cited: 157 -
Novel molecular targets for urothelial carcinoma.
Expert opinion on therapeutic targets.
2015
Information Resource
GET IT
Times cited: 9 -
Myelodysplastic syndromes: toward a risk-adapted treatment approach.
Expert review of hematology.
2013
Information Resource
GET IT
Times cited: 19 -
Sustained remission in a patient with myelodysplastic syndrome and a complex karyotype after erythropoiesis-stimulating therapy followed by colonic T-cell lymphoblastic lymphoma.
Leukemia & lymphoma.
2012
Article
GET IT
Times cited: 2 -
Dabigatran etexilate: what do hospitalists need to know?.
Journal of hospital medicine.
2011
Information Resource
GET IT
Times cited: 5 -
Identifying circulating tumor stem cells that matter: the key to prognostication and therapeutic targeting.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
2011
Article
GET IT
Times cited: 16 -
Cancer is an ancient disease: the case for better palaeoepidemiological and molecular studies.
Nature reviews. Cancer.
2011
Article
GET IT
Times cited: 10 -
Mental nerve neuropathy: frequently overlooked clinical sign of hematologic malignancies.
The American journal of medicine.
2011
Article
GET IT
Times cited: 6 -
Targeting hematogenous spread of circulating tumor cells by a chemotactic drug-eluting IVC filter to prevent pulmonary and systemic metastasis.
Medical hypotheses.
2009
Academic Article
GET IT
Times cited: 5 -
Update on perioperative bridging in patients on chronic oral anticoagulation.
Expert review of cardiovascular therapy.
2009
Information Resource
GET IT
Times cited: 6 -
Gastric Burkitt lymphoma associated with Efalizumab and Helicobacter pylori.
Leukemia & lymphoma.
2009
Article
GET IT
Times cited: 1